Sigilon Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sigilon Therapeutics Inc (SGTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sigilon Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 18M vs 95,590M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+33.7% annualized vs trailing 12 months), vs decelerating (-20.4%) for its tracked peer group.
- Growth: Sigilon Therapeutics Inc generated 104.7% revenue growth year over year in Q2 2023, vs 4.9% for its competitors combined.
- Profitability: Its -127.2% net margin compares with -0.8% for the peer group.
- Peer revenue share: Sigilon Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.80M compares with $1.00M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SGTX Sales vs. its Competitors, Q2 2023
Sigilon Therapeutics Inc reported revenue growth of 104.65 % year on year in Q2 2023, above its competitors' combined revenue growth of 4.94 %.
With a net margin of -127.22 %, Sigilon Therapeutics Inc reported lower profitability than its competitors (-0.82 %).
Sigilon Therapeutics Inc generated 0.03 % of the combined sales of its peer group, up from 0.02 % a year earlier.
API endpoints for this dataset
Sigilon Therapeutics Inc vs. its Competitors, Q2 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Sigilon Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sigilon Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sigilon Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (103) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sigilon Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 104.7% for Sigilon Therapeutics Inc. Sigilon Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Sigilon Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sigilon Therapeutics Inc | No | Yes | Yes | No |
| Competitors combined (92) | ||||
| High-Confidence Competitors (107) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 4) | 87.50 % (7 of 8) | 87.50 % (7 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SGTX Stock Performance relative to its Competitors
SGTX Stock Performance relative to High-Confidence Competitors
SGTX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Tango Therapeutics Inc | 282.9% | Outperformed |
| 2 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 3 | Apellis Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Longeveron Inc | 282.9% | Outperformed |
| 5 | Kalvista Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sigilon Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Sigilon Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Sigilon Therapeutics Inc |
56.22 | 17.65 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
 Teva Pharmaceutical Industries Limited |
50,407.63 | 14,020.00 |
 United Therapeutics Corporation |
25,740.52 | 3,154.50 |
 Viatris Inc |
23,161.30 | 14,737.30 |
| SUBTOTAL | 593,317.11 | 96,243.23 |
Sign in to see all competitors of Sigilon Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sigilon Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sigilon Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Sigilon Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Denali Therapeutics Inc | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Shuttle Pharmaceuticals Holdings Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Innate Pharma Sa | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Novo Nordisk A | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Nyxoah Sa | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Outlook Therapeutics | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Ocular Therapeutix | Company report | 85% |
| REGENXBIO | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Kodiak Sciences | Company report | 85% |
| Journey Medical Corp | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Opthea | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Peak Bio Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Point Pharmaceuticals | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| OCUP | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Xeris Biopharma Holdings Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Opus Genetics Inc | Company report | 85% |
| Mannkind Corporation | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| UCB | Company report | 85% |
| Bayer | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Scholar Rock | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Graybug Vision | Company report | 85% |
| Janssen | Company report | 85% |
| Inflarx N V | Company report | 85% |
| 4D Molecular Therapeutics | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Hoffmann-La Roche Ltd. | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Fresh Tracks Therapeutics Inc | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Generic Pharmaceuticals | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Organon and Co | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Wave Life Sciences Ltd | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Precision Biosciences Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Sigilon Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Sigilon Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
| Bridgebio Pharma Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Sigilon Therapeutics Inc .
Sigilon Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sigilon Therapeutics Inc | 56 | 802,455 | -1,374,545 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| Teva Pharmaceutical Industries Limited | 50,408 | 412,960 | 14,963 |
| United Therapeutics Corporation | 25,741 | 2,253,214 | 936,357 |
| Viatris Inc | 23,161 | 491,243 | -13,690 |
| PEERS TOTAL | 593,261 | 996,145 | 107,706 |
Sign in to see all peers for Sigilon Therapeutics Inc .
Sigilon Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| United Therapeutics Corporation | UNITED STATES 97.12 % |
| Ultragenyx Pharmaceutical Inc | North America 52.02 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sigilon Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 37.89 % (avg) | +62.1 pp |
| Operating Margin | -174.66 % | industry median | -60.8 pp |
| EBITDA Margin | -159.59 % | -6.23 % (avg) | -153.4 pp |
| Capital Intensity (Capex / Revenue) | 2.95 % | 7.58 % (avg) | -4.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sigilon Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 0.7x | 4.3x | -3.6x |
| Return on Equity | -83.83 % | industry aggregate | -94.77 % |
| Return on Invested Capital | -36.01 % | -9.83 % (avg) | -26.18 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Sigilon Therapeutics Inc's Strategic Group Map
Sigilon Therapeutics Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Sigilon Therapeutics Inc's trailing-12-month revenue growth of 76.8% and operating margin of -174.7% compares with an average of 53.1% growth and -82.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Sigilon Therapeutics Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Sigilon Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.95 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Sigilon Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Sigilon Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Sigilon Therapeutics Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sigilon Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+33.7% annualized vs trailing 12 months).
Weaknesses
- Operating margin 60.8 points below the industry median.
- Return on equity 94.8 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (62.60 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-20.4% annualized).
Methodology: see Methodology: SWOT Analysis.
Sigilon Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sigilon Therapeutics Inc | 1.17 | 2.28 | 0.39 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Teva Pharmaceutical Industries Limited | 0.26 | 0.96 | 2.09 |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
Sign in to see all peers for Sigilon Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sigilon Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sigilon Therapeutics Inc | Q2 2023 | +104.6 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -1.9 % | -46.3 % |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| PEERS TOTAL | +8.5 % | +147.0 % |
Sign in to see all peers for Sigilon Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sigilon Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sigilon Therapeutics Inc | Q2 2023 | - | +27.5 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -10.2 % | +200.0 % |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
Sign in to see all peers for Sigilon Therapeutics Inc .
Sigilon Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sigilon Therapeutics Inc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Teva Pharmaceutical Industries Limited | 1.26% | 1.96% | 6.37% |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
| Viatris Inc | - | - | - |
Sign in to see all peers for Sigilon Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sigilon Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sigilon Therapeutics Inc | - | 3.18 |
| Amgen Inc | 28.60 | 6.57 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| Teva Pharmaceutical Industries Limited | 57.07 | 3.60 |
| United Therapeutics Corporation | 20.17 | 8.16 |
| Viatris Inc | - | 1.57 |
| PEERS AVERAGE | 57.19 | 6.16 |
Sign in to see all peers for Sigilon Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.